RxDoctor Payments Data

Robert Summerlee, MD

Gastroenterology · Bradenton, FLNPI 1174596050

Payments from drug & device makers

$1,381in general payments, 2019–2025

Across 61 payments — averaging $22.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$409
  • Pfizer$190
  • Boston Scientific$174
  • Aimmune Therapeutics, Inc.$143
  • Johnson & Johnson$117
  • Gilead$65
  • plus $285 from 13 others

What the payments were for

  • Food & beverage$1,24990%
  • Education$13210%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,381 in reported general payments places this provider in the 30th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$344,455
Medicare patients
1,288
Services billed
3,592

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin77$249,239
Humira(Cf) PenAdalimumab18$147,769
OcalivaObeticholic Acid12$123,291
CreonLipase/Protease/Amylase50$110,634
LinzessLinaclotide81$89,454
ZenpepLipase/Protease/Amylase17$64,184
ViberziEluxadoline34$61,501
ClenpiqSod Picosulf/Mag Ox/Citric Ac251$43,434
Mesalamine61$25,292
MotegrityPrucalopride Succinate27$24,881
Dexlansoprazole DrDexlansoprazole38$16,745
MovantikNaloxegol Oxalate16$10,036
Pantoprazole Sodium548$6,810
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates101$6,406
Colestipol Hcl42$5,236

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess, Viberzi$409$261,589165 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$15$249,23977 claims
Intercept Pharmaceuticals, Inc.Ocaliva$21$123,29112 claims
Aimmune Therapeutics, Inc.Zenpep$143$64,18417 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$52$24,88127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Bradenton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →